In summary, this real-world cohort study suggests that among patients with type 2 diabetes and bipolar disorder, SGLT-2 inhibitor therapy is associated with a lower risk of suicide-related events compared to DPP-4 inhibitor therapy. Here, SLC5A2 is linked to bipolar disorder.